Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Rhea-AI Summary

Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in therapies for allergic and immunological conditions, announced that CEO Jill C. Milne, Ph.D., will participate in a fireside chat at the Jefferies Healthcare Conference. The event is scheduled for June 6th at 10:00am ET in New York, NY. A webcast of the presentation will be available live and as an archived replay for 30 days on the company's investor relations website.

Positive

• Astria Therapeutics' participation in a prominent healthcare conference may increase visibility and investor interest.
• CEO Jill C. Milne's presentation could provide valuable insights into the company's strategy and future plans.

Negative

• No specific financial or clinical updates were provided in the announcement, offering new information for investors.
• The webcast and replay access may not capture the full context or details of the presentation, potentially limiting investor understanding.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6^th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530854297/en/

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What event will Astria Therapeutics (ATXS) participate in on June 6th?

Astria Therapeutics will participate in a fireside chat at the Jefferies Healthcare Conference on June 6th at 10:00am ET.

How can I watch the Astria Therapeutics presentation at the Jefferies Healthcare Conference?

The presentation will be webcast live and can be accessed via the link provided in the company's press release. An archived replay will be available for 30 days after the event.

Who will represent Astria Therapeutics at the Jefferies Healthcare Conference?

Jill C. Milne, Ph.D., the CEO of Astria Therapeutics, will represent the company at the conference.

Where can I find the archived replay of Astria Therapeutics' presentation at the Jefferies Healthcare Conference?

The archived replay will be available in the investors section of Astria Therapeutics' website for 30 days following the event.